Table 1 Patient and disease characteristics at baseline (please note that comorbidities add up to more than 31 patients, since patients suffered from more than one disease).
Characteristics | Number of Patients (%) |
|---|---|
Sex | |
Male | 25 (80.6%) |
Female | 6 (19.4%) |
ECOG Status | |
0–1 | 29 (93.5%) |
2 | 2 (6.5%) |
Median age (range), years | 59 (44–78) |
Primary tumor site | |
Oral cavity | 11 (35.5%) |
Larynx | 3 (9.7%) |
Hypopharynx | 8 (25.8%) |
Oropharynx | 9 (29.0%) |
p16 status (oropharyngeal carcinoma) | |
Positive | 3 (33.3%) |
Negative | 5 (55.6%) |
Not evaluable | 1 (11.1%) |
Alcohol abuse | |
No | 10 (37.0% |
Yes | 17 (63.0%) |
Not evaluable | 4 |
Nicotine abuse | |
No | 2 (7.1%) |
Yes | 26 (92.9%) |
Not evaluable | 3 |
Cycles (range) | 3 (1–9) |
Median duration of treatment | 2.1 months |
Previous treatment | |
Surgery alone | 1 (3.2%) |
Surgery plus radiotherapy | 2 (6.5%) |
Surgery plus concomitant chemoradiotherapy | 5 (16.1%) |
Primary radiotherapy | 2 (6.5%) |
Primary concomitant chemoradiotherapy | 14 (45.2%) |
Primary radioimmunotherapy | 3 (9.6%) |
Radioimmunotherapy | 4 (12.9%) |
Extent of disease | |
Locoregional recurrence alone | 17 (54.8%) |
Metastatic disease alone | 8 (25.8%) |
Locoregional recurrence plus metastatic disease | 6 (19.4%) |
Nutritional status | |
Patients at risk of severe weight loss (BMI <20) | 15 (48.4%) |
Severe weight loss after radiotherapy ( >5% body weight loss in 6 months) | 1 (3.2%) |
Comorbidities | 16 (51.6%) |
Myocardial infarction | 2 |
Peripheral vascular disease | 5 |
Chronic obstructive pulmonary disease | 6 |
Diabetes mellitus | 4 |
Polycystic kidney disease | 1 |
Chronic kidney disease or | 4 |
Renal failure during chemoradiation | |
Chronic liver disease | 4 |
Stroke | 1 |
Perforation of the stomach | 2 |
Atrial fibrillation | 2 |
Second malignancy treated with curative intent | 3 |
